Australia markets closed

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.14+0.46 (+5.99%)
At close: 1:00PM EST
8.19 +0.05 (+0.61%)
After hours: 04:57PM EST

Atea Pharmaceuticals, Inc.

125 Summer Street
Boston, MA 02110
United States
857 284 8891

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 56

Key executives

NameTitlePayExercisedYear born
Dr. Jean-Pierre Sommadossi Ph.D.Founder, Chairman, CEO & Pres902.99kN/A1956
Dr. Janet M.J. HammondChief Devel. Officer728.32kN/A1960
Dr. Maria Arantxa Horga M.D.Chief Medical Officer367.56kN/A1968
Ms. Andrea J. CorcoranCFO, Exec. VP of Legal & Sec.N/AN/A1962
Mr. Wayne Foster CPA, CPASr. VP of Fin. & Admin.N/AN/A1968
Ms. Jonae R. BarnesSr. VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Paul J. FanningSr. VP of HRN/AN/A1958
Mr. Steven GoodExec. VP of Preclinical ScienceN/AN/AN/A
Mr. Adel Moussa Ph.D.Exec. VP of ChemistryN/AN/AN/A
Mr. Xiao-Jian Zhou Ph.D.Exec. VP of Early Stage Devel.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Corporate governance

Atea Pharmaceuticals, Inc.’s ISS governance QualityScore as of 26 September 2021 is 9. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.